| abstract |
The present invention includes the following general formula: (Where Het is oxazol-5-yl, pyridin-4-yl or pyrazol-4-yl; R 1 / R 2 independently of one another is hydrogen, lower alkyl, lower alkoxy or halogen; W is —CH 2 — or —CH 2 CH 2 —; X is CR 3 R 4 or NR 5 ; R 3 is hydrogen or lower alkyl; R 4 is — (CH 2 ) n -phenyl optionally substituted with halogen, lower alkoxy, halogen substituted lower alkyl, halogen or lower alkyl substituted lower alkoxy; R 5 is CHR-phenyl or CH 2 CHR-phenyl optionally substituted with halogen, lower alkoxy, halogen-substituted lower alkyl, halogen or lower alkyl-substituted lower alkoxy, or CHR-pyridine-2, 3 or 4-yl; R is hydrogen or lower alkyl; n is 0 or 1) Or a pharmaceutically acceptable acid addition salt thereof, a racemic mixture or a corresponding enantiomer thereof and / or an optical isomer thereof. Said compound is schizophrenia, obsessive-compulsive personality disorder, depression, bipolar disorder, anxiety, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive impairment, Down syndrome, autism spectrum disorder, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, It can be used to treat addiction of nervous system drugs selected from Huntington's disease, stroke, radiation therapy, chronic stress, alcohol, opiates, methamphetamine, phencyclidine and cocaine. |